Update zur personalisierten Diagnostik und Behandlung krebskranker Kinder

doi:10.1055/s-0033-1347183

Klinische Pädiatrie, Table of Contents

Klin Padiatr 2013; 225(03): 107-109
DOI: 10.1055/s-0033-1347183

Editorial

Update zur personalisierten Diagnostik und Behandlung krebskranker Kinder

Update: Personalized Diagnostics and Therapies for Pediatric Cancer Patients

Abstract

Full Text

References

Literatur
1 Blackmore C, Coppes MJ, Narendran A. Candidate genes and potential targets for therapeutics in Wilms’ tumour. Clin Transl Oncol 2010; 12: 597-605
2 Bochennek K, Esser R, Lehrnbecher T et al. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma. Klin Padiatr 2012; 224: 139-142
3 Broadhead ML, Clark JC, Myers DE et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011; doi: 10.1155/2011: 959248
4 Corbacioglu S. Early phase clinical trials in pediatric hematology and oncology. Klin Padiatr 2012; 224: 197-200
5 Creutzig U, Henze G, Bielack S et al. Krebserkrankungen im Kindesalter. Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Ärzteblatt 2003; 100: A842-A852
6 De Preter K, Mestdagh P, Vermeulen J et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011; 17: 7684-7692
7 De Preter K, Vermeulen J, Brors B et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010; 16: 1532-1541
8 Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037
9 Fischer M, Bauer T, Oberthür A et al. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010; 29: 865-875
10 Fischer M, Spitz R, Oberthür A et al. Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 2008; 220: 137-146
11 Grunewald TG, Greulich N, Kontny U et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr 2012; 224: 124-131
12 Gustafson WC, Matthay KK. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert Rev Neurother 2011; 11: 1411-1423
13 Haase R, Elsner K, Merkel N et al. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298 A>C polymorphisms on MTX-related toxicity. Klin Padiatr 2012; 224: 156-159
14 Hennes E, Zahn S, Lopes LF et al. Molecular genetic analysis of bilateral ovarian germ cell tumors. Klin Padiatr 2012; 224: 359-365
15 Heukamp LC, Thor T, Schramm A et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science Translat Med 2012; 4: 141ra91
16 Jain S, Xu R, Prieto VG et al. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol 2010; 3: 416-428
17 Janoueix-Lerosey I, Schleiermacher G, Michels E et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009; 27: 1026-1033
18 Jones DT, Jäger N, Kool M et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100-105
19 Kool M, Korshunov A, Remke M et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123: 473-484
20 Lawrenz B, Henes M, Neunhoeffer E et al. Fertility preservation in girls and adolescents before chemotherapy and radiation – review of the literature. Klin Padiatr 2011; 223: 126-130
21 Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211
22 Molenaar JJ, Domingo-Fernández R, Ebus ME et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 2012; 44: 1199-1206
23 Northcott PA, Jones DT, Kool M et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12: 818-834
24 Northcott PA, Korshunov A, Pfister SM et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012; 8: 340-351
25 Northcott PA, Korshunov A, Witt H et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-1414
26 Northcott PA, Shih DJ, Peacock J et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012; 488: 49-56
27 Oberthuer A, Berthold F, Warnat P et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24: 5070-5078
28 Oberthuer A, Hero B, Berthold F et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010; 28: 3506-3515
29 Øra I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol 2011; 21: 217-228
30 Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008; 55: 97-120
31 Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671
32 Potratz J, Jürgens H, Craft A et al. Ewing sarcoma: biology-based therapeutic perspectives. Pediatr Hematol Oncol 2012; 29: 12-27
33 Pugh TJ, Weeraratne SD, Archer TC et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488: 106-110
34 Rausch T, Jones DT, Zapatka M et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148: 59-71
35 Reinhardt D, Von Neuhoff C, Sander A et al. Genetic prognostic factors in childhood acute myeloid leukemia. Klin Padiatr 2012; 224: 372-376
36 Rossig C, Juergens H. Aetiology of childhood acute leukaemias: current status of knowledge. Radiat Prot Dosimetry 2008; 132: 114-118
37 Royer-Pokora B, Graf N. Wilms tumors arising at young age: a genetic basis to distinguish subgroups for individualized therapy. J Clin Oncol 2011; 29: e485-e486
38 Schramm A, Schulte JH, Klein-Hitpass L et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005; 24: 7902-7912
39 Schwartzentruber J, Korshunov A, Liu XY et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482: 226-231
40 Speleman F, De Preter K, Vandesompele J. Neuroblastoma genetics and phenotype: a tale of heterogeneity. Semin Cancer Biol 2011; 21: 238-244
41 Stanulla M, Cario G, Meissner B et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia – a perspective from the BFM Study Group. Blood Cells Mol Dis 2007; 39: 160-163
42 Taylor MD, Northcott PA, Korshunov A et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123: 465-472
43 Vermeulen J, De Preter K, Naranjo A et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009; 10: 663-671
44 Witt H, Mack SC, Ryzhova M et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20: 143-157
45 Witt O, Milde T, Deubzer HE et al. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klin Padiatr 2012; 224: 398-403
46 Wittmann S, Wunder C, Zirn B et al. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 2008; 47: 386-395